Yusuke Nakamura to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications Yusuke Nakamura has written about Antineoplastic Agents, Hormonal.
Connection Strength
1.693
-
Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2017 04 15; 23(8):2019-2026.
Score: 0.470
-
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
Score: 0.351
-
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011 Feb; 11(2):185-93.
Score: 0.317
-
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
Score: 0.103
-
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet. 2012 Apr 01; 21(7):1665-72.
Score: 0.084
-
Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(1):137-45.
Score: 0.083
-
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10; 28(8):1287-93.
Score: 0.074
-
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008 May; 99(5):995-9.
Score: 0.065
-
Genome-wide screening by cDNA microarray of genes associated with matrix mineralization by human mesenchymal stem cells in vitro. Biochem Biophys Res Commun. 2002 Jan 11; 290(1):381-90.
Score: 0.042
-
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. J Clin Oncol. 2019 08 01; 37(22):1982-1983.
Score: 0.035
-
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Res Treat. 2015 Jan; 149(2):517-23.
Score: 0.026
-
VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014 May 28; 16(3):R53.
Score: 0.025
-
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. World J Surg Oncol. 2009 Nov 12; 7:88.
Score: 0.018